

tLNP-circular RNA in vivo CAR for treatment of autoimmune diseases Roi Mashiach:

Company name Ribox Therapeutics * Website www.riboxtx.com * CEO name Weiyi Zheng*

“Rewriting Biology In Vivo: The Age of Cellular Reprogramming.”

Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. • Core Technology: What is the technology, its uniqueness, and its value proposition? • Product Profile/Pipeline: Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. • Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. • What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Answers to all these questions can be found in the presentation